« In line with our expectation! »
Why are we using QMSI in oncology?
Tumors are very heterogeneous. Investigating the co-localization of drugs and biomarkers is key to defining the PK/PD relationship. At ImaBiotech, we are able to quantify and localize drugs and metabolites as well as biomarkers with a multimodal imaging platform called Multimaging. This platform has been integrated into classical PK/PD study to offer a better predictive tool.
What can we delivered?
We deliver in a single experiment tissue distribution of drug, metabolites, targets and biomarkers of efficacy for a quick and precise drug efficacy and safety evaluation
Early Whole Body PK
- In vivo dosing (xenograft or allograft tumor in rodents)
- Quantitative Mass Spectrometry Imaging of drug and metabolites
- Histology (Hematoxylin & Eosin, and others staining techniques)
Target Exposure
- QMSI drug + metabolites
- QMSI biomarkers (metabolites, lipids, peptides)
- Immunohistochemistry of protein biomarker (receptors, enzymes,etc…)
In situ PK/PD
- MSI of substructure of interest
- Histology
- Identification of specific pathways relating to tumor activities (proliferation, necrosis, apoptosis, differentiation)
- Statistical analysis to identify biomarker involved in diseases or drug responses
How de we deliver reveal information in complex tissues?
ImaBiotech has developed a platform of Mass Spectrometry Imaging with instruments, a dedicated software and a list of biomarkers to evaluate the efficacy and toxicity of a drug.
The platform is a combination of :
- Label free imaging at 10μm spatialresolution
- Quantification of drug and metabolites down to the microenvironment of the tumor
- Immuno-histology with the ability to overlay MSI, IHC and histological information within multimodal platform and dedicated software (Multimaging™, visit the dedicated page)
- Efficacy and Safety Biomarkers monitoring
- High Resolution Mass Spectrometers (R>200,000)
We have experience with different animal and tumor models
- Human biopsies
- Orthotopic models
- Xenograft tissues on :
- Breast Cancer
- Colon Cancer
- Brain Cancer
- Prostate Cancer
Testimonies
Jinping Gan
, Senior Principal Scientist at BMS
Mika Pykäläinen
, Head of Bioanalytical Operations, at Orion
« Just one word: Excellent ! »
Oncology project in 2015
, Anonymous
« I have worked with ImaBiotech on some straightforward analyses and some that were a bit more challenging technically. In all cases, communication with ImaBiotech business and scientific personnel was excellent, and I feel confident that we obtained the best possible data given the experimental constraints we had to accommodate. »
Oncology project in 2016
, Anonymous
« Good quality work, very responsive and flexible team »
We also provide more classical studies under GLP or Non-GLP environment
PK & PD studies
We propose PK and PD studies to support early to late stages drug discovery process (animals: rabbit, dog, swine or other species upon customer request).
- Drug Disposition/Pharmacokinetics (ADME)
- DMPK
- Pharmacodynamics
- In Vitro and In Vivo Topical Absorption Studies (FFPE, 3D models, fresh frozen tissue)
Toxicology
We allow you to complete toxicological studies and propose several species such as dogs and rabbits and other non-rodent species.
- Acute Toxicity
- Subacute Toxicity (Repeated Dose)
- Sub-chronic Exposure
- Chronic Exposure
Models
We propose pathological models and naturally diseased animals for research (rabbit, dog …)
Ressources
Application Notes
Multimaging™ Applied to Skin
Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI : application to prostate cancer.
MSI Has Never Been So Close to You
Publications
Tryp-Kyn Pathway in Immuno-Oncology
Altered metabolic landscape in IDH‐mutant gliomas
Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI : application to prostate cancer.
